Genscript Biotech Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Weihui Shao
- Full Time Employees
- 6,165
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Dah Sing Financial Centre Hong Kong Hong Kong
- IPO Date
- Jan 21, 2016
- Website
- genscript.com
- Similar Companies
- Business
- Genscript Biotech Corporation (1548.HK), founded in 2002 and headquartered in Nanjing, China, with primary U.S. operations in Piscataway, New Jersey, operates as a leading global biotechnology company providing life science research products and services; it offers gene synthesis, oligonucleotide synthesis, peptide synthesis, protein production and purification, antibody development and production including monoclonal antibodies via platforms like MonoRab and PrecisionAb, custom peptides with modifications such as fluorescent labels and biotinylation, CRISPR gene editing, next-generation sequencing services, molecular biology tools and reagents, life-science equipment and consumables, as well as preclinical drug development services encompassing in vitro and in vivo pharmacology, protein engineering, and cell therapy solutions; the company serves pharmaceutical, biotech, academic institutions, and researchers worldwide across North America, Europe including a Netherlands subsidiary, Asia-Pacific with a new Sydney hub, and other regions. Genscript Biotech organizes into key segments including the Life Science Group for research services and products, and ProBio for contract development and manufacturing organization (CDMO) activities in biologics and cell/gene therapies. In recent developments, ProBio opened a flagship U.S. plasmid and viral vector manufacturing facility in Hopewell, New Jersey in June 2025 to advance cell and gene therapy production; the company formed a strategic partnership with NSG Bio in April 2025 to drive biotechnology innovation, announced a collaboration with Bioelectronica in May 2025 for antibody development using single B-cell screening technology, expanded its partnership with Roche ongoing since 2011, earned an EcoVadis Silver Medal in July 2025 ranking in the top 15% globally for sustainability, released its 2024 ESG report in April 2025, achieved SBTi verification of carbon reduction goals in February 2025, and reported FY 2024 financial results in March 2025.
Company News
Genscript Biotech Corporation (GNNSF) Q2 2026 Earnings Call Transcript
Genscript Biotech Corporation (GNNSF) Q4 2025 Earnings Call Transcript
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
Genscript Biotech Corporation (GNNSF) Q2 2025 Earnings Call Transcript
GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation
GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader
GenScript Biotech Corporation Reports FY 2024 Results
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development
GenScript Biotech Sets Up New Operations and Logistics Hub in Sydney, Australia
GenScript Biotech Corporation (GNNSF) Q2 2024 Earnings Call Transcript
GenScript Biotech Reports First Half 2024 Results
GenScript Biotech Corporation Launches FLASH Gene Service: The Fastest and Most Affordable Gene Synthesis Solution on the Market
GenScript Biotech Shares Drop After U.S. Lawmakers Scrutinize Chinese Ties
US lawmakers ask FBI for briefing on GenScript Biotech's links to China
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications
Multiply Labs and GenScript Biotech Corporation Collaborate to Automate the Cell Isolation and Enrichment Phase of Cell Therapy Manufacturing
GenScript Biotech Releases 2023 ESG Report: Deepening Green Development Practices, Constructing Sustainable Future Blueprint
Multiply Labs and GenScript Biotech Corporation Collaborate to Automate the Cell Isolation and Enrichment Phase of Cell Therapy Manufacturing
GenScript Biotech officially joins SBTi to fulfill its sustainability commitment
GenScript Biotech Receives EcoVadis Bronze Medal for Outstanding Sustainability Performance